Humacyte, Inc.

Equities

HUMA

US44486Q1031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:46:38 14/05/2024 BST			5-day change	1st Jan Change
6.465 ^USD	+17.97%		+40.78%	+128.52%

05-10	Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024
03-28	Transcript : Humacyte, Inc. - Special Call

Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 22, 2024 at 11:00 am

Humacyte, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 25.11 million compared to USD 3.72 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.04 a year ago.

Latest news about Humacyte, Inc.

Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024	05-10
Transcript : Humacyte, Inc. - Special Call	03-28
Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024	03-22
Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	03-22	MT
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Humacyte, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-22	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	03-08	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	03-01	MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell	03-01	MT
Humacyte Prices $40.2 Million Share Offering	03-01	MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	02-09	MT
Humacyte Shares Rise After FDA Grants Priority Review to Vascular Trauma Treatment	02-09	DJ
Sector Update: Health Care Stocks Mixed in Afternoon Trading	02-09	MT
Humacyte Shares Rise as Application for Potential Vascular Trauma Treatment Gets Priority Review from FDA	02-09	MT
Humacyte Gets Speedy FDA Review of Bioengineered Tissue in Vascular Trauma	02-09	DJ
Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application	02-09	CI
Humacyte Seeks FDA Approval of Bioengineered Tissue for Treatment of Vascular Injuries	12-12	MT
Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel for the Treatment of Vascular Trauma	12-12	CI
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	12-11	MT
Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel?? (HAV??) in the Treatment of Vascular Trauma	11-17	CI
Transcript : Humacyte, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Humacyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel?? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model	16/10/23	CI
Humacyte Jumps 8.2% After Hours Thursday; CEO Laura Niklason, CFO Dale Sander to Present at Cantor Global Healthcare Conference Sept. 28	22/09/23	MT

Chart Humacyte, Inc.

Duration

Period

More charts

Company Profile

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - Benchmark Healthcare House Virtual Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.48 USD

Average target price

7.667 USD

Spread / Average Target

+39.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMACYTE, INC.	+128.52%	653M
MODERNA, INC.	+28.34%	48.16B
IQVIA HOLDINGS INC.	-0.57%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+10.72%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.94%	18.96B
BIO-TECHNE CORPORATION	+8.31%	12.92B
MEDPACE HOLDINGS, INC.	+29.70%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.41%	11.77B

Other Biotechnology & Medical Research